HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acne ads

This article was originally published in The Rose Sheet

Executive Summary

Nature's Cure will work with Children's Advertising Review Unit of the Council for Better Business Bureaus to ensure ads for the acne treatment do not run during children's programming, watchdog group announces Oct. 28. CARU guidelines prohibit advertising medications or drugs to children. Nature's Cure commercial targeting teenagers has aired on the Toon Disney network between 8 p.m. and 8:30 p.m, when "the primary audience for this programming, according to recent demographics, is children under the age of 12," CARU notes...

You may also be interested in...



Top FDA Officials: Agency Actively Cracking Down On Medical Products With Sham COVID-19 Claims

US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority to ask for records from drug manufacturers in lieu of conducting facility inspections, but they didn’t say whether the agency would – or even could – ask the same of device makers. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.

Execs On The Move: Conformis And EyeKor Make Major Management Changes

Knee implant manufacturer Conformis Inc. brings aboard new chief financial officer/treasurer and operations SVP; imaging and data management software company EyeKor promoted its president/CTO to CEO; and more.

Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.

UsernamePublicRestriction

Register

RS012558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel